Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8182072 | 0.96 | STAT3 (0.44) | STAT3STAT1TERT | |
| Acetic Acid SCHEMBL9582363 | 0.94 | STAT3 (0.44) | STAT3STAT1 | |
| Acetic Acid SCHEMBL9582779 | 0.94 | STAT3 (0.44) | STAT3STAT1 | |
| SCHEMBL9583481 | 0.90 | STAT3 (0.40) | STAT3STAT1TERT | |
| Hydrochloric Acid SCHEMBL13274495 | 0.88 | STAT3 (0.53) | STAT3STAT1TERT | |
| SCHEMBL5143471 | 0.85 | STAT3 (0.44) | STAT3STAT1 | |
| SCHEMBL19718106 | 0.82 | STAT3 (0.39) | STAT3STAT1 | |
| SCHEMBL29677253 | 0.82 | TERT (0.44) | TERT | |
| SCHEMBL18418 | 0.82 | TERT (0.44) | TERT | |
| SCHEMBL2439280 | 0.82 | STAT3 (0.30) | STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006021403-A1 | BICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | claimed |
| US-6620805-B1 | Drug delivery of antihepatitis viricide to hepatocytes | YALE UNIVERSITY | 2003-09-16 | — | — | US | claimed |
| US-6610478-B1 | Delivering nucleic acids to bacterial cells. The method does not require manipulation of the bacteria and is therefore particularly suited to delivery of nucleic acids to bacteria in natural environments such as bodies of animals | YALE UNIVERSITY | 2003-08-26 | — | — | US | claimed |
| US-12011611-B2 | Illumination devices for inducing biological effects | KNOW BIO, LLC (US) | 2024-06-18 | — | — | US | disclosed |
| US-11986666-B2 | Illumination devices for inducing biological effects | KNOW BIO, LLC (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4362943-A2 | NEW DRUG APPLICATION | Centre National de la Recherche Scientifique (FR) | 2024-05-08 | — | — | EP | disclosed |
| US-20240075312-A1 | ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS | KNOW BIO, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240024699-A1 | ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS | KNOW BIO LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302293-A1 | ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS | KNOW BIO LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11752359-B2 | Illumination devices for inducing biological effects | KNOW BIO, LLC (US) | 2023-09-12 | — | — | US | disclosed |
| EP-0726781-B1 | IN VIVO AGENTS COMPRISING RADIOACTIVE METAL-ION CHELATES WITH ACIDIC SACCHARIDES AND GLYCOSAMINOGLYCANS, GIVING IMPROVED SITE-SELECTIVE LOCALIZATION, UPTAKE MECHANISM, SENSITIVITY AND KINETIC-SPATIAL PROFILES | ACCESS PHARMA INC (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001054764-A2 | BIOABSORBABLE BRACHYTHERAPY DEVICE | BIOSURFACE ENGINEERING TECHNOLOGIES, INC (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0894011-A2 | DELIVERY OF NUCLEIC ACIDS BY PORPHYRINS | INNOVIR LABORATORIES, INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997033622-A2 | DELIVERY OF NUCLEIC ACIDS BY PORPHYRINS | INNOVIR LABORATORIES, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
| EP-0345171-B1 | Metalloporphyrine derivatives, their therapeutical use and their use in the preparation of hybrid molecules | CENTRE NAT RECH SCIENT (FR) | 1995-12-13 | — | — | EP | disclosed |
| US-5236914-A | Antitumor agents, viricides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5230998-A | Viricides | AIDA DEVELOPMENT CORPORATION | 1993-07-27 | — | — | US | disclosed |
| WO-1989012049-A1 | DERIVATIVES OF METALLOPORPHYRINES, THEIR PREPARATION, APPLICATION FOR THERAPEUTICAL PURPOSES AND USE IN PREPARING HYBRID MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1989-12-14 | — | — | WO | disclosed |
| EP-0345171-A1 | Metalloporphyrine derivatives, their therapeutical use and their use in the preparation of hybrid molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | STAT3 1427/4885STAT1 4192/4885TERT 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.